Colorectal cancer

Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

Friday, January 15, 2021 - 1:00pm

The data were presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI 2021).

Key Points: 
  • The data were presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI 2021).
  • The complete dose-finding part of this phase Ib/II study evaluated the safety, feasibility and recommended phase II dose of NBTXR3 for patients with locally advanced (T3 to T4) or unresectable rectal cancer.
  • NBTXR3 is a novel, potentially first-in-class product candidate designed to destroy tumors through physical cell death when activated by radiotherapy.
  • Nanobiotixs novel, potentially first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients.

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

Friday, January 15, 2021 - 1:01pm

NuTide:302 is a three-part study investigating NUC-3373, NuCanas targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer.

Key Points: 
  • NuTide:302 is a three-part study investigating NUC-3373, NuCanas targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer.
  • The ASCO GI presentation highlighted data from 37 patients treated in Part I of the study who received NUC-3373 either as monotherapy or in combination with leucovorin.
  • Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy and five patients experienced tumor shrinkage.
  • Our objective is to replace 5-FU and capecitabine with NUC-3373 as the backbone of treatment for patients with colorectal cancer.

Ashion Analytics to Present Data on the Value of Comprehensive Genomic Profiling of Gastrointestinal Cancers by Utilizing the GEM ExTra® Test

Friday, January 15, 2021 - 9:55am

Background: Gastrointestinal cancers (GIC) account for 26% of global cancer incidence and 35% of cancer-related deaths.

Key Points: 
  • Background: Gastrointestinal cancers (GIC) account for 26% of global cancer incidence and 35% of cancer-related deaths.
  • Methods: GEM ExTra assay was performed on 844 paired samples (ages 18-90 years, median= 61 years).
  • Overall, comprehensive genomic profiling enabled detection of established and novel actionable alterations, including fusions, which may have gone undetected using hotspot panels.
  • "Our study provides a comprehensive analysis of molecular signatures across 22 different gastrointestinal cancers using whole exome and whole transcriptome analysis.

New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®

Tuesday, January 12, 2021 - 7:45pm

These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.

Key Points: 
  • These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.
  • Study is among the first to evaluate the use of a colorectal cancer screening method in patients between ages of 45-49.
  • Cologuard is a U.S. Food & Drug Administration (FDA)-approved, non-invasive stool DNA test for colorectal cancer for average-risk people.
  • In September 2019, the FDA approved Cologuard for average-risk individuals beginning at age 45, expanding the Cologuard label to include this critical younger adult population.

CES 2021 Jun Zhi integrated Taiwan's top research teams to develop SAA Cancer Screening Services

Tuesday, January 12, 2021 - 2:34pm

TAIPEI, Jan. 12, 2021 /PRNewswire/ -- Jun Zhi, a Taiwan-based biomedical team, developed the SAA Cancer Screening Service.

Key Points: 
  • TAIPEI, Jan. 12, 2021 /PRNewswire/ -- Jun Zhi, a Taiwan-based biomedical team, developed the SAA Cancer Screening Service.
  • Jun Zhi developed SAA Cancer Screening Services by integrating top research teams from Academia Sinica, National Tsing Hua University, National Yang-ming University, and Kaohsiung Medical University's Chung-Ho Memorial Hospital.
  • In its current stage of development, SAA Cancer Screening is able to detect gastric cancer and colorectal cancers.
  • This innovative biotech product helped convince Taiwan Tech Arena (TTA) to select JUN ZHI as one of the 100 featured Taiwanese startups showcased at CES 2021.

Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas in a Prospective, Multi-Center Clinical Study

Tuesday, January 12, 2021 - 2:00pm

Compared with the FDA-approved mSEPT9 (methylated septin 9) blood test, Freenomes multiomics blood test showed much higher sensitivity (41% vs. 22%)1 for detecting AAs.

Key Points: 
  • Compared with the FDA-approved mSEPT9 (methylated septin 9) blood test, Freenomes multiomics blood test showed much higher sensitivity (41% vs. 22%)1 for detecting AAs.
  • That means with a blood test such as Freenomes multiomics test, not only can we detect colorectal cancer, but we may be able to prevent colorectal cancer altogether.
  • A blood test that can detect both advanced adenomas and early stage colorectal cancer could be an important tool in the fight against colorectal cancer.
  • Importantly, these new results also showed that Freenomes multiomics blood test detected twice as many advanced adenomas as cell-free DNA methylation-only or single-protein approaches.

Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium

Tuesday, January 12, 2021 - 2:03pm

SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology's 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 15-17, 2021.

Key Points: 
  • SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology's 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 15-17, 2021.
  • Natera will have one oral and one poster presentation, each describing the clinical performance of Signatera in patients with colorectal cancer (CRC).
  • "We are delighted to share the results of these studies with the ASCO GI community," said Alexey Aleshin, MD, Natera's Senior Medical Director of Oncology.
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

NEC Releases 'WISE VISION Endoscopy' in Europe and Japan

Tuesday, January 12, 2021 - 1:56am

TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.
  • This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
  • Colorectal cancer is the most common cancer in Japan(1), and the second most common in Europe(2).
  • NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue.

NEC Releases “WISE VISION Endoscopy” in Europe and Japan

Tuesday, January 12, 2021 - 1:00am

NEC Corporation (NEC; TOKYO: 6701) today announced the development of WISE VISION Endoscopy, an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.

Key Points: 
  • NEC Corporation (NEC; TOKYO: 6701) today announced the development of WISE VISION Endoscopy, an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.
  • This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
  • View the full release here: https://www.businesswire.com/news/home/20210111006087/en/
    Colorectal cancer is the most common cancer in Japan (*1), and the second most common in Europe (*2).
  • NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue.

SOLVD Health Prepares to Launch Clinical Study of Non-Invasive Colorectal Cancer Screening Test

Wednesday, January 6, 2021 - 7:00pm

CARLSBAD, Calif., Jan. 6, 2021 /PRNewswire/ -- SOLVD Health ( www.solvdhealth.com ), a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, is preparing to launch a U.S. clinical study of its non-invasive colorectal cancer (CRC) screening test, LifeKit Prevent.

Key Points: 
  • CARLSBAD, Calif., Jan. 6, 2021 /PRNewswire/ -- SOLVD Health ( www.solvdhealth.com ), a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, is preparing to launch a U.S. clinical study of its non-invasive colorectal cancer (CRC) screening test, LifeKit Prevent.
  • "Colonoscopy is the current gold standard for colorectal cancer screening because it accurately detects cancer as well as precancerous adenomas," said Keri Donaldson , MD, CEO of SOLVD Health.
  • Early research has shown that our test is effective at detecting both, which could be a gamechanger for colorectal cancer screening."
  • SOLVD Health's prospective clinical trial will enroll up to 12,000 individuals to validate its test for the detection of colorectal cancer and adenomas.